Table 1. Clinical-pathological data of the patients involved in this study and their association with overall survival.
| Parameter | No. of patients in TaqMan analysis | No. of patients in microarray analysis |
|---|---|---|
| Histology | ||
| ERMS | 66 (41%) | 31 (37%) |
| ARMS | 90 (55%) | 53 (63%) |
| PAX3-FOXO1 fusion gene-positive | 45 | 30 |
| PAX7-FOXO1 fusion gene-positive | 12 | 8 |
| Fusion gene-negative | 33 | 15 |
| RMS not otherwise specified | 7 (4%) | 0 |
| Total | 163 | 84 |
| Gender (M/F) | 91/72 | 47/37 |
| Median age | 5 (0–23) | 5.5 (0–21) |
| Primary tumour location | ||
| Favourable | 58 | 32 |
| Unfavourable | 79 | 50 |
| Unknown | 26 | 2 |
| SIOP stage | ||
| Stage I | 46 | 25 |
| Stage II | 44 | 26 |
| Stage III | 21 | 9 |
| Stage IV | 43 | 22 |
| Unknown | 9 | 2 |
| Metastasis | ||
| Present at diagnosis | 43 | 22 |
| Absent at diagnosis | 108 | 61 |
| Unknown | 12 | 1 |
| Median survival | ||
| Median follow-up time | 4.0 ya | |
| Overall survival | 9.6 y | |
| N of events (N patients) | 61 (159) | |
| Event-free survival | 2.8 y | |
| N of events (N patient) | 79 (159) |
Abbreviations: ARMS=alveolar RMS; ERMS=embryonal RMS; RMS= rhabdomyosarcoma.
a
On the basis of patients with censored data.